Alexandra Drakaki, MD, PhD | Authors

Articles

Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma

February 15, 2020

Alexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.